The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following ...

Afgelopen vrijdag, op 16 mei werd de CEO van Novo Nordisk, Lars Fruergaard Jørgensen onverwacht ontslagen als CEO van het ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

Multiple Danish businesses on Friday reaffirmed their confidence in growth and further cooperation with China amid optimism about the economic prospects and vast opportunities of the world's ...

Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phas ...

In another note of news, a key aide to HHS Secretary Robert F. Kennedy Jr. said that popular GLP-1 weight loss drugs -- Novo Nordisk's ( NVO) Wegovy (semaglutide) and Eli Lilly's ( LLY) Zepbound ...